Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

What Is Allogeneic Cell Therapy, And What’s Driving This Market’s 25%+ Annual Global Growth?

PHOENIX, AZ / ACCESSWIRE / August 24, 2023 / Biotechnology company Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) seems to be witnessing success in the allogeneic cell therapy market.

Creative Medical Technology Holdings, Inc., Thursday, August 24, 2023, Press release picture

In Q4 2022, the company - best known for its regenerative approach to immunotherapy, endocrinology, urology, gynecology and orthopedics - made a significant announcement regarding the successful development of an allogeneic cell line known as AlloStem™. AlloStem™ is a cell line that is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Following FDA approval, the program - referred to as CELZ-201 - is now being utilized in an early type 1 diabetes clinical trial. It will continue to undergo development for the treatment of both type 1 and type 2 Diabetes.

The company has also started using its AlloStem™ line to help treat chronic back pain for its StemSpine® procedure. It reports that this combination resulted in a greater than 90% reduction in narcotic usage associated with chronic back pain, a greater than 80% reduction in pain score and a greater than 50% reduction in the Oswestry score in patients treated with AlloStem™.

So what is allogeneic cell therapy? Allogeneic cell therapy is a type of treatment that uses cells donated by a healthy person to treat a patient with an otherwise untreatable disease. These cells can come from different sources, including bone marrow, blood or umbilical cord blood. These types of therapies have shown immense promise in the medical community.

Allogeneic cell therapy can provide patients with a potentially curative treatment option where other traditional therapies have been unsuccessful. As a relatively new field, research into allogeneic cell therapies is ongoing, and the future seems promising for patients who suffer from these diseases. Companies like Argan Inc are also exploring the potential benefits of allogeneic cells.

With the necessary endorsement from the FDA and an ongoing clinical trial, Creative Medical Technology's recent developments set the stage for innovative treatment options that could significantly improve the lives of patients grappling with diabetes and other diseases. The global market size for allogeneic cell therapy was $255.6 million in 2022, and it is expected to grow at a CAGR of 27.4% from 2023 to 2030, highlighting the value of ongoing research. As the company remains steadfast in its commitment to medical innovation, its efforts have the potential to yield enhanced health outcomes for individuals worldwide.

Featured photo by Diabetesmagazijn.nl on Unsplash.

Contact:

Apex The Equity Group Inc., Devin Sullivan
dsullivan@equityny.com

SOURCE: Creative Medical Technology Holdings, Inc.



View source version on accesswire.com:
https://www.accesswire.com/776624/What-Is-Allogeneic-Cell-Therapy-And-Whats-Driving-This-Markets-25-Annual-Global-Growth

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.